Combination inhibitors of influenza virus replication

JP7577652B2Active Publication Date: 2024-11-05COCRYSTAL PHARMA INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021521129
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-10-17
Filing Date
2019-10-17
Publication Date
2024-11-05
Estimated Expiration
2039-10-17

Smart Images

  • Figure 0007577652000002
    Figure 0007577652000002
  • Figure 0007577652000003
    Figure 0007577652000003
  • Figure 0007577652000004
    Figure 0007577652000004
Patent Text Reader

Abstract

Provided herein are combinations of compounds that can inhibit influenza virus replication, reduce influenza virus load, and / or treat influenza.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates generally to combinations of inhibitors of influenza virus replication and methods of treating or preventing influenza infection or replication by administering the combinations to a patient in need of such treatment. [Background technology]

[0002] Influenza spreads worldwide in seasonal epidemics, resulting in hundreds of thousands of deaths each year and millions in pandemic years. For example, the 20th century saw three influenza pandemics that killed tens of millions of people, each caused by the emergence of a new virus strain in humans. Often, these new strains result from the spread of existing influenza viruses from other animal species to humans.

[0003] Influenza is primarily transmitted from person to person via large virus-laden droplets produced when an infected person coughs or sneezes. These large droplets can then settle on upper respiratory tract mucosal surfaces of susceptible individuals near the infected person (e.g., within about 6 feet). Transmission can also occur by direct or indirect contact with respiratory secretions, such as touching a surface contaminated with influenza virus and then touching the eyes, nose, or mouth. Adults may be able to spread influenza to others from one day before symptoms appear up to about five days after symptoms begin. Children and people with weakened immune systems may be contagious for 10 days or more after the onset of symptoms.

[0004] Influenza viruses are RNA viruses of the family Orthomyxoviridae, which includes five genera: influenza Avirus, influenza Bvirus, influenza Cvirus, isavirus, and thogotovirus.

[0005] The influenza A virus genus is responsible for seasonal and pandemic influenza epidemics. The influenza A virus genus has one species, influenza A virus, and wild waterfowl are the natural host of the great variety of influenza A. Sometimes, the virus can be transmitted to other species and then cause devastating outbreaks in poultry or cause human influenza pandemics. Type A virus is the most contagious human pathogen of the three influenza types and causes the most severe disease. Type A virus can be subdivided into various serotypes based on the antibody response to these viruses. The serotypes identified in humans, ordered by known human pandemic deaths, are: H1N1 (caused the Spanish influenza in 1918), H2N2 (caused the Asian Influenza in 1957), H3N2 (caused the Hong Kong Flu in 1968), H5N1 (pandemic threat during the 2007-2008 influenza season), H7N7 (potential pandemic threat), H1N2 (endemic in humans and pigs), H9N2, H7N2, H7N3, and H10N7.

[0006] The influenza B virus genus is responsible for seasonal influenza and has one species, influenza B virus. Influenza B infects humans almost exclusively and is less common than influenza A. The only other animal known to be susceptible to influenza B infection is the seal. This type of influenza mutates at a rate two to three times slower than type A, resulting in low genetic diversity and only one influenza B serotype. Due to the lack of antigenic diversity, some immunity to influenza B is usually acquired during childhood. However, influenza B mutates enough that sustained immunity is not possible. This low rate of antigenic change, combined with its limited host range (which prevents interspecies antigenic shift), ensures that influenza B pandemics do not occur.

[0007] The influenza C virus genus has one species, influenza C virus, which infects humans and pigs and can cause severe illness and localized epidemics, but influenza C appears to be less common than the other types and usually causes milder disease in children.

[0008] Influenza viruses are highly similar in structure across serotypes and genera. The influenza virus genome consists of eight single-stranded RNAs packaged into rod-like structures of various sizes known as ribonucleoprotein complexes (RNPs). Each RNP contains a unique viral RNA, multiple copies of a scaffolding nucleoprotein, and a heterotrimeric viral polymerase consisting of PA, PB1, and PB2 subunits that catalyze the transcription and replication of the viral genome. Recent biochemical and structural studies of the influenza polymerase complex have provided insights into the understanding of the mechanism of cap-snatching and RNA synthesis by influenza polymerase. Briefly, the PB2 cap-binding domain first sequesters the host pre-mRNA by binding to the 5' cap. Then, the endonuclease subunit PA cleaves 10-13 nucleotides of the captured pre-mRNA downstream of the cap. The PB2 subunit then rotates approximately 700 times to direct the capped primer to the PB1 polymerase active site. The PB1 subunit directly interacts with both the PB2 and PA subunits. These subunits contain highly conserved domains among different influenza strains, making them attractive anti-influenza drug targets. In addition to the polymerase complex, the influenza genome encodes its own neuraminidase (NA), hemagglutinin (HA), nucleoprotein (NP), matrix proteins M1 and M2, and nonstructural proteins NS1 and NS2. NA is the target of the antiviral drugs oseltamivir (Tamiflu®), laninamivir (Inavir®), peramivir, and zanamivir (Relenza®). These drugs inhibit the enzymatic activity of NA, thus delaying the release of progeny viruses from infected cells.

[0009] Influenza incurs direct costs due to lost productivity and associated medical procedures, as well as indirect costs of preventive measures. In the United States, influenza causes a total cost of over $10 billion annually, but it is estimated that a future pandemic could result in direct and indirect costs of hundreds of billions of dollars. The costs of prevention are also high. Governments around the world are spending billions of dollars preparing and planning for a potential H5N1 avian influenza pandemic, with costs associated with purchasing medicines and vaccines, as well as developing strategies for disaster training and improved border control.

[0010] Current treatment options for influenza include vaccination and chemotherapy or chemoprevention with antiviral medications. Vaccination against influenza with influenza vaccines is often recommended for high-risk groups such as children and the elderly, or for people with asthma, diabetes, or heart disease. However, people can still get influenza even after being vaccinated. Vaccines are formulated again each flu season for some specific influenza strains, but cannot include all strains that are actively infecting people around the world during that flu season. It takes manufacturers about six months to formulate and produce the millions of doses that are needed to deal with a seasonal epidemic. Sometimes new or overlooked strains become prominent during that period and infect people despite being vaccinated (such as with H3N2 Fujian influenza during the 2003-2004 flu season). Because the vaccine takes about two weeks to become effective, it is also possible to become infected just before vaccination and become ill from the very strain that the vaccine is supposed to prevent.

[0011] Furthermore, the effectiveness of these influenza vaccines is variable. Due to the high mutation rate of the virus, a particular influenza vaccine typically provides protection for only a few years. Because influenza viruses change rapidly over time and different strains become dominant, a vaccine formulated for one year may not be effective the next year.

[0012] Due to the absence of RNA proofreading enzymes, the RNA-dependent RNA polymerase of influenza vRNA produces one nucleotide insertion error for every 10,000 nucleotides, the approximate length of influenza vRNA. Thus, every newly produced influenza virus is a mutant-antigenic drift. The separation of the genome into eight separate segments of vRNA allows for the mixing or reassortment of vRNAs if two or more viral lineages infect a single cell. The resulting rapid changes in viral genetics result in antigenic shift, allowing the virus to infect new host species and rapidly overcome protective immunity.

[0013] Antiviral drugs can also be used to treat influenza, with NA inhibitors being particularly effective, but the virus can develop resistance to approved NA antiviral drugs. It has also been well documented that multi-drug resistant pandemic influenza A viruses will emerge. Drug-resistant pandemic influenza A will be a major threat to public health. In addition to drug-resistant influenza A viruses, NA inhibitors have been approved for the treatment of early influenza infections (within 48 hours of influenza symptom onset).

[0014] Thus, there remains a need for drugs to treat influenza infection, including drugs with an expanded treatment window and / or reduced susceptibility to viral titers. Summary of the Invention

[0015] The present disclosure relates generally to methods of treating influenza, inhibiting influenza virus replication, reducing influenza virus load, and compounds and compositions that may be used in such methods.

[0016] Provided herein is a method of treating or preventing influenza infection or replication in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of (1) 3-(2-(5-chloro-1H-pyrrolo[2,3-b]]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, and (2) a second influenza therapeutic selected from the group consisting of baloxavir marboxil, baloxavir, a neuraminidase inhibitor, and favipiravir, or a pharmaceutically acceptable salt or solvate thereof.

[0017] Additionally, the disclosure provides a combination comprising: (1) 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, and (2) baloxavir or baloxavir marboxil, or a pharmaceutically acceptable salt or solvate thereof; (3) a neuraminidase inhibitor, such as oseltamivir, oseltamivir acid, zanamivir, laninamivir, peramivir, or a pharmaceutically acceptable salt or solvate thereof.

[0018] Further provided are methods of administering a safe and effective amount of the combinations disclosed herein to a biological sample or to a patient.

[0019] Also provided herein are methods of reducing the amount of influenza virus in a biological sample or a patient by administering to the biological sample or to the patient a safe and effective amount of the combination disclosed herein.

[0020] Further provided is a method of treating or preventing influenza A or influenza B infection in a patient comprising administering to the patient a safe and effective amount of the combination disclosed herein.

[0021] Also provided is the use of a combination as described herein for inhibiting or reducing influenza virus replication in a biological sample or a patient, for reducing the amount of influenza virus in a biological sample or a patient, or for treating influenza in a patient.

[0022] Further provided herein is the use of a combination as described herein for the manufacture of a medicament for treating influenza in a patient, for reducing the amount of influenza virus in a biological sample or a patient, or for inhibiting the replication of influenza virus in a biological sample or a patient.

[0023] The combinations disclosed herein can be co-formulated or can be administered separately to a subject, patient, or host. [Brief description of the drawings]

[0024] [Figure 1] 1 is a MacSynergy™ II graph showing the effect of the combination of Compound 1 and Baloxavir in an assay of influenza virus A / PR / 8 / 34 (H1N1) replication in MDCK cells. Synergy / antagonism is shown relative to 95% confidence intervals. Throughout, Compound 1 refers to 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid. [Diagram 2] 1 is a MacSynergy™ II graph showing the effect of the combination of Compound 1 and oseltamivir acid in a replication assay of influenza virus A / PR / 8 / 34 (H1N1) in MDCK cells. Synergy / antagonism is shown relative to the 95% confidence interval. [Diagram 3]MacSynergy™ II graph showing the effect of the combination of Compound 1 and Favipiravir in an assay of influenza virus A / PR / 8 / 34 (H1N1) replication in MDCK cells. Synergy / antagonism is shown relative to the 95% confidence interval. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] Disclosed herein are combinations of anti-influenza compounds (antiviral agents) and the use of these combinations in inhibiting influenza virus activity.In some embodiments, the disclosure generally relates to the use of the combinations described herein for inhibiting influenza virus replication in biological samples or patients, for reducing the amount of influenza virus (reducing viral titer) in biological samples or patients, and for treating or preventing influenza in patients.The combinations disclosed herein can be co-formulated or can be administered separately to subjects, patients, or hosts.

[0026] The combination includes, inter alia, 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid or a pharma- ceutically acceptable salt or solvate thereof, or alternatively referred to herein as "Compound 1," as an active ingredient. This compound is believed to be a CAP-binding PB2 domain inhibitor.

[0027] In various embodiments, compound 1 is used in combination with a second antiviral agent as a prophylactic or therapeutic agent against influenza, for example, influenza virus replication or infection. The influenza can be a pandemic or drug-resistant pandemic / seasonal influenza virus. In some cases, the influenza is influenza A or influenza B. The second antiviral agent can be a polymerase inhibitor, an endonuclease inhibitor, or a neuraminidase inhibitor, or an influenza vaccine. Further discussion regarding the timing of administration of compound 1 and the second antiviral agent is provided below.

[0028] In some embodiments, a combination is provided that includes 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, and a second antiviral agent, wherein in some cases the second antiviral agent is selected from the group consisting of baloxavir, baloxavir marboxil, a neuraminidase inhibitor, and favipiravir, or a pharmaceutically acceptable salt or solvate thereof.

[0029] When administered separately, administration of compound 1 and the second antiviral agent can be simultaneous (e.g., within about 5-10 minutes of each other) or separated by one or more hours (e.g., 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 26 hours, 48 ​​hours, or 72 hours). In some cases, compound 1 can be administered before the second antiviral agent. In some other cases, compound 1 can be administered after the second antiviral agent. Further discussion regarding the timing of administration of compound 1 and the second antiviral agent is provided below.

[0030] In other embodiments, a combination is provided that includes a) a therapeutically effective amount of 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, and b) a therapeutically effective amount of a second antiviral agent, wherein in some cases the second antiviral agent is selected from the group consisting of baloxavir, baloxavir marboxil, a neuraminidase inhibitor, and favipiravir, or a pharmaceutically acceptable salt or solvate thereof.

[0031] In another embodiment, the use of the therapeutically effective amount of the combination disclosed herein is provided for treating or preventing influenza virus infection or replication in human patients.For example, the influenza virus can be pandemic or drug-resistant pandemic / seasonal influenza virus.In some cases, the influenza virus can be influenza A or influenza B.Other influenza viruses are described below.

[0032] In other embodiments, there is provided the use of 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, in combination with a second antiviral agent, in some cases the second antiviral agent is selected from the group consisting of baloxavir, baloxavir marboxil, a neuraminidase inhibitor, and favipravir, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment or prevention of influenza virus infection or replication.

[0033] In other embodiments, there is provided the use of 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyridin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, in combination with a second antiviral agent, wherein in some cases the second antiviral agent is selected from the group consisting of baloxavir, baloxavir marboxil, a neuraminidase inhibitor, and favipiravir, or a pharmaceutically acceptable salt or solvate thereof, for inhibiting influenza virus infection or replication.

[0034] In other embodiments, methods are provided for the treatment or prevention of influenza virus infection or replication, comprising administering to a human patient having or at risk of influenza virus infection a combination of a) a therapeutically effective amount of 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, and b) in some cases, a therapeutically effective amount of a second antiviral agent selected from the group consisting of baloxavir, baloxavir marboxil, a neuraminidase inhibitor, and favipravir, or a pharmaceutically acceptable salt or solvate thereof.

[0035] In other embodiments, methods are provided for treating or preventing influenza virus infection or replication, comprising administering 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, at a dose of about 10-1,000 mg / kg, and in some cases, a therapeutically effective amount of a second antiviral agent selected from the group consisting of baloxavir, baloxavir marboxil, a neuraminidase inhibitor, and favipiravir, or a pharmaceutically acceptable salt or solvate thereof, to a human patient having or at risk of influenza infection.

[0036] In another embodiment, a pharmaceutical composition for the treatment or prevention of influenza virus infection or replication in a patient is provided, comprising 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl))-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof as an active ingredient, wherein the composition is administered in combination with a second antiviral agent, and in some cases, the second antiviral agent is selected from the group consisting of baloxavir, baloxavir marboxil, a neuraminidase inhibitor, and favipravir, or a pharmaceutically acceptable salt or solvate thereof.

[0037] In other embodiments, a method of inhibiting endonuclease activity of influenza polymerase in an influenza A or B virus is provided, comprising contacting the virus with a combination of compound 1 disclosed herein and a second antiviral agent.

[0038] In other embodiments, methods are provided for treating or preventing influenza A or influenza B infection in a host, comprising administering to the host a therapeutic amount of a combination of compound 1 and a second antiviral agent disclosed herein.

[0039] In another embodiment, a method is provided for reducing endonuclease activity of influenza polymerase in an influenza A or B virus in a host, comprising administering to the host a therapeutic amount of a combination of compound 1 and a second antiviral agent disclosed herein.

[0040] In other embodiments, methods are provided for reducing influenza virus replication in a host, comprising administering to the host a therapeutic amount of a combination of compound 1 and a second antiviral agent disclosed herein.

[0041] In some embodiments, a method of using the disclosed combination of compound 1 and a second antiviral agent is provided, which further comprises contacting influenza virus with a therapeutically effective amount of a third antiviral agent or administering a therapeutically effective amount of a third antiviral agent to a host. For example, in some embodiments, the method can further comprise administering an influenza vaccine to the host before, after, or simultaneously with the combination. In some cases, the disclosed method comprises administering an influenza vaccine without compound 1 and another antiviral agent (i.e., the vaccine is the second antiviral agent). In some cases, compound 1 is administered simultaneously with an influenza vaccine. In some cases, compound 1 is co-formulated with an influenza vaccine.

[0042] In other embodiments, there is provided the use of a combination of compound 1 disclosed herein and a second antiviral agent in the treatment of influenza A or influenza B virus infection.

[0043] In another embodiment, there is provided the use of a combination of Compound 1 and a second antiviral agent disclosed herein in the manufacture of a medicament for the treatment of influenza A or influenza B virus infection.

[0044] In another embodiment, there is provided a combination comprising: a) 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3]-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof; b) baloxavir, baloxavir marboxil, or a pharmaceutically acceptable salt or solvate thereof; and c) a neuraminidase inhibitor.

[0045] Neuraminidase inhibitors for use in the methods disclosed herein can be oseltamivir, oseltamivir acid, zanamivir (Relenza®), laninamivir (Inavir®), or peramivir, or a pharmaceutically acceptable salt or solvate thereof. Endonuclease inhibitors can be used in the methods disclosed herein, and in some cases, the endonuclease inhibitors are referred to as "PA" inhibitors. In various embodiments, the endonuclease inhibitor can be baloxavir or baloxavir marboxil, or a pharmaceutically acceptable salt or solvate thereof. Polymerase inhibitors can be used in the methods disclosed herein, and in some cases, the polymerase inhibitors are referred to as "PB1" inhibitors. In various embodiments, the polymerase inhibitor can be favipiravir, or a pharmaceutically acceptable salt or solvate thereof. Influenza vaccines can be used in the methods disclosed herein.

[0046] In various embodiments of the aspects disclosed herein, the second antiviral agent is baloxavir, baloxavir marboxil, or a pharmaceutically acceptable salt or solvate thereof. In other embodiments of the aspects disclosed herein, the second antiviral agent is a neuraminidase inhibitor (e.g., more specifically, oseltamivir, oseltamivir acid, or a pharmaceutically acceptable salt or solvate thereof). In other embodiments of the aspects disclosed herein, the second antiviral agent is favipiravir, or a pharmaceutically acceptable salt or solvate thereof.

[0047] How to use The combinations described herein can be used to reduce viral titers in biological samples (e.g., infected cell cultures) or in humans (e.g., lung viral titers in patients).

[0048] As used herein, the terms "influenza virus-borne condition," "influenza infection," or "influenza" are used interchangeably to mean disease caused by infection with an influenza virus.

[0049] Influenza is an infection that affects birds and mammals caused by influenza viruses. Influenza viruses are RNA viruses of the Orthomyxoviridae family, which includes five genera: influenza A virus, influenza B virus, influenza C virus, isavirus, and thogotovirus. The influenza A virus genus has one species, influenza A virus, which can be classified into different serotypes: H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3H7N9, and H10N7 based on the antibody response to these viruses. The influenza B virus genus has one species, influenza B virus. Influenza B infects humans almost exclusively and is less common than influenza A. The influenza C virus genus has one species, influenza virus C virus, which can infect humans and pigs and cause severe illness and local epidemics. However, influenza C virus is less common than other types and usually appears to cause mild disease in children.

[0050] In some embodiments, the influenza or influenza virus is associated with influenza A or B viruses. In some embodiments, the influenza or influenza virus is associated with influenza A viruses. In some specific embodiments, the influenza A virus is H1N1, H2N2, H3N2, H7N9, or H5N1. In some embodiments, the disclosed combinations are effective to inhibit the growth or replication of pandemic or drug-resistant pandemic / seasonal influenza viruses.

[0051] In humans, common symptoms of influenza are chills, fever, sore throat, muscle aches, severe headache, cough, weakness, and general discomfort. In more severe cases, influenza can cause pneumonia, which can be fatal, especially in children and the elderly. Although influenza is often confused with the common cold, it is a much more serious illness and is caused by a different type of virus. Influenza can cause nausea and vomiting, especially in children, but these symptoms are more characteristic of an unrelated gastroenteritis, sometimes called "stomach flu" or "24-hour flu."

[0052] Influenza symptoms can develop very suddenly, 1-2 days after infection. Usually the first symptom is chills or a chilly feeling, but fever is also common early in infection, with temperatures ranging from 38-39 °C (about 100-103 °F). Many people become so ill that they are bedridden for several days with aches and pains throughout the body, which are exacerbated in the back and legs. Influenza symptoms may include body aches, especially in the joints and throat, extreme chills and fever, fatigue, headache, inflamed or red eyes, skin (especially the face), mouth, throat and nose, and abdominal pain (in children with influenza type B). Influenza symptoms are nonspecific and overlap with many pathogens ("influenza-like illness"). Laboratory data is usually required to confirm the diagnosis.

[0053] The terms "disease," "disorder," and "condition" may be used interchangeably herein to refer to an influenza virus-mediated medical or pathological condition.

[0054] The terms "subject", "host" and "patient" are used interchangeably. The terms "subject", "host" and "patient" may refer to animals (e.g., birds such as chickens, quails, or turkeys, or mammals), specifically mammals such as non-primates (e.g., cows, pigs, horses, sheep, rabbits, guinea pigs, rats, cats, dogs, or mice), or primates (e.g., monkeys, chimpanzees, or humans), more specifically humans. In some embodiments, the subject is a non-human animal, such as a farm animal (e.g., horses, cows, pigs, or sheep) or a pet (e.g., dog, cat, guinea pig, or rabbit). In a preferred embodiment, the subject is a "human".

[0055] The term "biological sample" as used herein includes, but is not limited to, a cell culture or extract thereof; a biopsy obtained from a mammal or an extract thereof; blood, saliva, urine, feces, semen, tears, or other bodily fluids or extracts thereof.

[0056] As used herein, the term "inhibition of influenza virus replication" includes both a reduction in the amount of viral replication (e.g., a reduction of at least 10%) and up to and including a complete cessation of viral replication (i.e., a 100% reduction in the amount of viral replication). In some embodiments, influenza virus replication is inhibited by at least 50%, at least 65%, at least 75%, at least 85%, at least 90%, or at least 95%.

[0057] Influenza virus replication can be measured by any suitable method known in the art. For example, influenza virus titers can be measured in biological samples (e.g., infected cell cultures) or in humans (e.g., lung virus titers in patients). More specifically, for cell-based assays, in each case, cells are cultured in vitro, virus is added to the culture in the presence or absence of a test agent, and virus-dependent endpoints are evaluated after a suitable length of time. In a typical assay, Madin-Darby canine kidney cells (MDCK) and standard tissue culture-adapted influenza strain A / Puerto Rico / 8 / 34 can be used. The first type of cell assay that can be used in the present disclosure relies on the death of infected target cells, a process called cytopathic effect (CPE), where viral infection causes the exhaustion of cell sources and eventual cell lysis. In the first type of cellular assay, a low percentage of cells (usually 1 / 10 to 1 / 1000) in a well of a microtiter plate is infected, the virus is allowed to replicate several times over 48 to 72 hours, and then the amount of cell death is measured using the reduction in cellular ATP content compared to uninfected controls. The second type of cellular assay that can be used in this disclosure relies on the proliferation of virus-specific RNA molecules in infected cells, and RNA levels are measured directly using branched DNA hybridization techniques (bDNA). In the second type of cellular assay, a small number of cells are first infected in a well of a microtiter plate, the virus is allowed to replicate in the infected cells and spread to additional rounds of cells, the cells are then lysed, and the viral RNA content is measured. The assay is stopped early, usually after 18 to 36 hours, while all target cells are still viable. Viral RNA is quantified by hybridization to specific oligonucleotide probes immobilized in the wells of the assay plate, followed by amplification of the signal by hybridization with an additional probe coupled to a reporter enzyme.

[0058] As used herein, "virus titer" or "titer" is a measure of virus concentration. Titer testing can use serial dilutions to obtain approximate quantitative information from an analytical procedure that is essentially only evaluated as positive or negative. The titer corresponds to the highest dilution factor that still results in a positive reading. For example, a positive reading in the first eight serial two-fold dilutions is converted to a titer of 1:256. A specific example is virus titer. To determine titer, some dilutions are diluted 10 -1 , 10 -2 , 10 -3 , , 10 -8 The lowest concentration of virus that still infects cells is the virus titer.

[0059] As used herein, the terms "treat," "treatment," and "treating" refer to both therapeutic and prophylactic treatments. For example, therapeutic treatment includes the reduction or amelioration of the progression, severity, and / or duration of an influenza virus-mediated condition, or the amelioration of one or more symptoms (specifically, one or more discernible symptoms) of an influenza virus-mediated condition, resulting from the administration of one or more therapies (e.g., one or more therapeutic agents, such as compounds or compositions described herein). In certain embodiments, therapeutic treatment includes the improvement of at least one measurable physical parameter of an influenza virus-mediated condition. In other embodiments, therapeutic treatment includes inhibiting the progression of an influenza virus-mediated condition, either physically, e.g., by stabilization of discernible symptoms, physiologically, e.g., by stabilization of physical parameters, or both. In other embodiments, therapeutic treatment includes the reduction or stabilization of influenza virus-mediated infection. Antiviral drugs can be used in community settings to treat people who already have influenza to reduce the severity of symptoms and reduce the number of days people are sick.

[0060] As used herein, the terms "prophylaxis", "prophylactic", "prophylactic use" and "prophylactic treatment" refer to any medical or public health procedure that aims to prevent rather than treat or cure a disease. As used herein, the terms "prevent", "prevention" and "preventing" refer to the reduction of the risk of acquiring or developing a given condition or the alleviation or inhibition of recurrence of said condition in a subject who is not ill but may be in the vicinity of or has been in the vicinity of a person who has the disease. The term "chemoprevention" refers to the use of medicines, e.g., small molecule drugs, rather than vaccines for the prevention of a disorder or disease.

[0061] Prophylactic use includes use in situations where an outbreak has been detected to prevent transmission or spread of infection in places where many people who are at high risk for serious influenza complications live in close proximity to one another (e.g., hospital wards, day care centers, prisons, nursing homes, etc.). Prophylactic use also includes use within populations that need protection from influenza but do not receive protection after vaccination (e.g., due to a weak immune system, etc.), where the vaccine is not available to them, or where they cannot receive the vaccine due to side effects. It also includes use two weeks after vaccination or any period after vaccination but before the vaccine is effective. Prophylactic use can also include treating people who have influenza but are not sick or are not considered at high risk for complications to reduce the chance of contracting influenza and transmitting it to high-risk people who are in close contact with them (e.g., health care workers, nursing home workers, etc.).

[0062] As used herein, and consistent with usage by the United States Centers for Disease Control and Prevention (US CDC), an influenza "outbreak" is defined as a sudden increase in acute febrile respiratory illness (AFRI) occurring within 48-72 hours in a group of people who are in close proximity to one another (e.g., the same area of ​​a nursing home, the same household, etc.) above normal background rates or when any subject in the population tests positive for influenza.

[0063] In some embodiments, the combinations are useful as preventative or prophylactic measures for patients, particularly humans, who are predisposed to complications resulting from infection with an influenza virus. The combinations can be useful in prophylactic methods in index cases or confirmed outbreak situations to prevent the spread of infection to the rest of the community or population.

[0064] As used herein, "effective amount" refers to an amount sufficient to induce a desired biological response. In the present disclosure, the desired biological response is to inhibit influenza virus replication, reduce the amount of influenza virus, or reduce or ameliorate the severity, duration, progression, or onset of influenza virus infection, prevent the progression of influenza virus infection, prevent the recurrence, occurrence, onset, or progression of symptoms associated with influenza virus infection, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy used against influenza infection. The exact amount of the compound administered to a subject depends on the mode of administration, the type and severity of infection, and the characteristics of the subject, such as general health, age, sex, weight, and tolerance to drugs. Those skilled in the art will be able to determine the appropriate dosage depending on these and other factors.

[0065] Thus, when 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl))-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid is co-administered with other antiviral agents, for example, with anti-influenza medication, the effective amount of the second agent will depend on the type of drug used. A safe amount is one that is associated with minimal or tolerable number and severity of side effects, as can be easily determined by one of skill in the art. Suitable doses are known for approved drugs and can be adjusted by one of skill in the art depending on the subject's condition, the type of condition(s) being treated, and the amount of compound described herein used. If no amount is specified, a safe and effective amount should be assumed. For example, 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl))-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid or a pharma- ceutically acceptable salt or solvate thereof can be administered to a subject in the dosage range of about 0.01 to 100 mg / kg body weight / day for therapeutic or prophylactic treatment.

[0066] As used herein, a "safe and effective amount" of a compound or composition described herein is an effective amount of the compound or composition that does not cause excessive or harmful side effects in the patient.

[0067] In general, the administration regimen can be selected according to various factors, including the disorder to be treated and the severity of the disorder; the activity of the specific compound used; the specific composition used; the age, weight, general health, sex, and diet of the patient; the administration time, administration route, and excretion rate of the specific compound used; the renal and hepatic function of the subject; and the specific compound or its salt used, the duration of treatment; the drugs used in combination with or simultaneously with the specific compound used, and similar factors well known in the medical field.Those skilled in the art can easily determine and prescribe the effective amount of the compound described herein required to treat, prevent, inhibit (completely or partially) or stop the progression of the disease.

[0068] Dosages of the compounds described herein can range from about 0.01 to about 100 mg / kg body weight / day, about 0.01 to about 50 mg / kg body weight / day, about 0.1 to about 50 mg / kg body weight / day, or about 1 to about 25 mg / kg body weight / day. It is understood that the total daily amount can be administered in a single dose or in multiple doses, such as twice a day (e.g., every 12 hours), three times a day (e.g., every 8 hours), or four times a day (e.g., every 6 hours).

[0069] For therapeutic treatment, the compounds described herein can be administered to a patient, for example, within 48 hours (or within 40 hours, or within less than 2 days, or within less than 1.5 days, or within 24 hours) of the onset of symptoms (e.g., stuffy nose, sore throat, cough, aches, fatigue, headache, and chills / sweats). Therapeutic treatment can be continued for any suitable period of time, such as, for example, 5 days, 7 days, 10 days, 14 days, etc. For prophylactic treatment during community outbreaks, the compounds described herein can be administered to a patient, for example, within 2 days of the onset of symptoms in index cases, and can be continued for any suitable period of time, such as, for example, 7 days, 10 days, 14 days, 20 days, 28 days, 35 days, 42 days, etc.

[0070] Combination therapy The combinations described herein can be administered alone or in further combination with additional suitable therapeutic agents, such as a third antiviral agent or vaccine. When employing combination therapy, a safe and effective amount can be achieved using a first amount of compound 1, i.e., 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharma- ceutically acceptable salt or solvate thereof, a second antiviral agent, and an amount of one or more third antiviral agents. In some cases, the third antiviral agent is a pyrazinecarboxamide antiviral compound, an influenza neuraminidase inhibitor, or an influenza PB1 polymerase domain inhibitor. Further therapeutic combinations can be achieved with additional suitable therapeutic agents (e.g., antiviral agents or vaccines).

[0071] Among the second antiviral agents suitable for use in these combinations is baloxavir (CAS No. 1985605-59-1), which is being developed by the Japanese pharmaceutical company Shionogi Co. as a marboxil prodrug (CAS No. 1985606-14-1; trade name Xofluza®) for the treatment of influenza A and B.

[0072] Also suitable as a second antiviral agent for use in these combinations is oseltamivir phosphate (CAS No. 204255-11-8; trade name (Tamiflu®)), which is a neuraminidase inhibitor being developed by Roche Pharmaceuticals as a medicine for the treatment or prevention of influenza infection.

[0073] Also suitable for use in these combinations is favipiravir (CAS No. 259793-96-9; T-705; trade name Avigan®), a pyrazine carboxamide derivative being developed by the Japanese pharmaceutical company Toyama Chemical Co., Ltd. for the treatment of RNA viruses, including influenza A and influenza B. The use of 200 mg tablets for the treatment of influenza is approved in Japan. For adults, favipiravir can be orally administered in an amount of 10 mg to 10,000 mg per day. In some embodiments, favipiravir can be orally administered in an amount of 100 mg to 4000 mg per day. In some embodiments, favipiravir can be orally administered in an amount of 1,600 mg twice daily on day 1, and 600 mg of favipiravir twice daily on days 2 through 5, for a total administration period of 5 days.

[0074] Kitano et al. report that the combination of baloxavir and a neuraminidase inhibitor synergistically inhibited influenza A / H1N1 virus replication in MDCK cells (Open Forum Infectious Diseases, 4, Issue suppl_1, 1 October 2017, Pages S371). Thus, in some embodiments, a combination is provided that includes 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3--d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid and baloxavir or baloxavir marboxil and a neuraminidase inhibitor. Neuraminidase inhibitors suitable for use in such combinations include, for example, oseltamivir, oseltamivir acid, zanamivir, laninamivir, and peramivir, or more specifically, oseltamivir phosphate, oseltamivir acid, zanamivir hydrate, laninamivir, and peramivir trihydrate.

[0075] In some embodiments of the present disclosure, compound 1, or a pharma- ceutically acceptable salt thereof, and the second antiviral agent are each administered in a safe and effective amount (i.e., each in an amount that would be therapeutically effective if administered alone). In some embodiments, compound 1 and the second antiviral agent are each administered in an amount that does not provide a therapeutic effect alone (subtherapeutic dose). In some embodiments, compound 1 can be administered in a safe and effective amount, while the second antiviral agent is administered in a subtherapeutic dose. In some embodiments, compound 1 can be administered in a subtherapeutic dose, while the second antiviral agent is administered in a safe and effective amount.

[0076] As used herein, the terms "combination therapy," "in combination," and "co-administration" or "coadministration" can be used interchangeably to refer to the use of two or more therapies (e.g., one or more prophylactic and / or therapeutic agents). The use of the terms does not restrict the order in which the therapies (e.g., prophylactic and / or therapeutic agents) are administered to a subject.

[0077] Co-administration can include administration of a first amount and a second amount of a compound of a combination in an essentially simultaneous manner, for example, in a single pharmaceutical composition, such as a capsule or tablet having a fixed ratio of the first amount and the second amount, or in multiple separate capsules or tablets for each. Moreover, such co-administration can also include using each compound of the combination in a sequential manner in any order.

[0078] In some embodiments, the present disclosure relates to a combination therapy method for inhibiting influenza virus replication in a biological sample or a patient, or for treating or preventing influenza virus infection in a patient using the compounds or pharmaceutical compositions of the present disclosure.Accordingly, the pharmaceutical compositions described herein also include compositions comprising 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid in combination with a second antiviral agent that exhibits anti-influenza virus activity.

[0079] Methods of use also include combinations of Compound 1 and a second antiviral agent, further in combination with another antiviral agent and / or vaccination with an influenza vaccine.

[0080] When the co-administration involves separate administration of a first amount of 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid and a second amount of a second antiviral agent, the 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid and the second antiviral agent are administered sufficiently close in time to obtain the desired therapeutic effect. For example, the period between each administration can range from minutes to hours and can be selected taking into account the properties of each compound, such as potency, solubility, bioavailability, plasma half-life, and kinetic profile, that result in the desired therapeutic effect. For example, 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid and the second antiviral agent can be administered in any order within about 24 hours of each other, within about 16 hours of each other, within about 8 hours of each other, within about 4 hours of each other, within about 1 hour of each other, or within about 30 minutes of each other.

[0081] More specifically, 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid is administered to the subject at least 1 hour (e.g., 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours) prior to administration of the second antiviral agent to the subject. , 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks prior to, simultaneously with, or subsequently thereto (e.g., 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after).

[0082] Co-administration of an amount of 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid described herein and an amount of a second antiviral agent can result in an enhanced or synergistic therapeutic effect, where the observed combined effect is greater than the additive effect that would be expected to result from separate administration of an amount of Compound 1 and an amount of a second antiviral agent.

[0083] As used herein, the term "synergistic" refers to a combination of the present disclosure that is more effective than the additive effects of the component compounds. A synergistic effect of a combination of therapies (e.g., a combination of prophylactic or therapeutic agents) allows one or more therapies to be used at lower dosages and / or administered less frequently to a subject. The ability to utilize lower dosages of a therapy (e.g., a prophylactic or therapeutic agent) and / or administer the therapy less frequently can reduce the toxicity associated with administration of the therapy to a patient without reducing the efficacy of the therapy in preventing, managing, or treating a disorder. Furthermore, a synergistic effect can improve the efficacy of agents in preventing, managing, or treating a disorder. Finally, a synergistic effect of a combination of therapies (e.g., a combination of prophylactic or therapeutic agents) can avoid or reduce harmful or undesirable side effects associated with the use of either therapy alone.

[0084] Furthermore, when using the combination therapies of the present disclosure, the component therapeutic agents can be administered such that the time periods between each administration can be longer (eg, days, weeks, or months).

[0085] The presence of synergy can be determined using a suitable method for evaluating drug interactions. Suitable methods include, for example, the Sigmoid-Emax equation (Holford, NHG and Scheiner, LB, Clin. Pharmacokinet. 6:429-453 (1981)), the Loewe addition equation (Loewe, S, and Muischnek, H., Arch. Exp. Pathol. Pharmacol. 114:313-326 (1926)) and the median-effect equation (Chou, TC and Talalay, P., Adv. Enzyme Regul. 22:27-55 (1984)). Each of the above-mentioned equations can be applied to experimental data to generate corresponding graphs that can be used to evaluate the effect of drug combinations. The corresponding graphs associated with the above-mentioned equations are the concentration-effect curve, the isobologram curve, and the combination index curve, respectively. MacSynergy™ II is a well-established graphics software that aids in the calculation of combination indices (Prichard and Shipman, 1990).

[0086] Anti-influenza vaccine The compounds described herein can be administered prophylactically in combination with anti-influenza vaccines. These vaccines can be administered, for example, by subcutaneous or intranasal administration. Vaccination by subcutaneous injection typically induces IgG antibodies with neutralizing activity in serum, which is highly effective in preventing the progression of the condition to more severe conditions such as pneumonia. However, in the upper respiratory tract mucosa, which is the site of infection, IgA is the main preventive component. Since IgA is not induced by subcutaneous administration, it can also be advantageous to administer the vaccine by intranasal route.

[0087] Definitions and General Terms The compounds of the present disclosure are defined herein by their chemical structure and / or chemical name. If a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.

[0088] Pharmaceutically acceptable salts and solvates The compounds described herein can be in free form or, where appropriate, as salts.Their pharmaceutically acceptable salts are particularly interesting, since they are useful for administering the compounds that are components of the combinations described herein for medical purposes.Pharmaceutically unacceptable salts are useful in the manufacturing process for isolation and purification purposes, and in some cases, are useful for use in the separation of stereoisomers of the compounds described herein or their intermediates.

[0089] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound that is suitable for use in contact with the tissues of humans and lower animals without undue adverse effects, such as toxicity, irritation, allergic response, and the like, within the scope of sound medical judgment, and commensurate with a reasonable benefit / risk ratio.

[0090] Pharmaceutically acceptable salts are well known in the art.For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference.The pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases.These salts can be prepared in situ during the final isolation and purification of compounds.

[0091] If the compounds described herein contain a basic group or a sufficiently basic bioisostere, an acid addition salt can be prepared by 1) reacting the purified compound in its free base form with a suitable organic or inorganic acid and 2) isolating the salt so formed. In practice, the acid addition salt may be the more convenient form for use, and use of the salt amounts to use of the free base form.

[0092] Examples of pharma- ceutically acceptable non-toxic acid addition salts are the salts of amino groups formed with inorganic acids such as hydrochloric, hydrobromic, phosphoric, sulfuric, and perchloric acids, or organic acids such as acetic, oxalic, maleic, tartaric, citric, succinic, or malonic acids, or by using other methods used in the art, such as ion exchange. Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glycolate, gluconate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydrogenphosphate, and the like. These include aryloxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like.

[0093] When the compounds described herein contain a carboxylic acid group or a sufficiently acidic bioisostere, a base addition salt can be prepared by 1) reacting the purified compound in its acid form with a suitable organic or inorganic base, and 2) isolating the salt thus formed. In practice, the use of a base addition salt may be more convenient, and the use of the salt form is essentially equivalent to the use of the free acid form. Salts derived from appropriate bases include alkali metal (e.g., sodium, lithium, and potassium), alkaline earth metal (e.g., magnesium, calcium), ammonium, and N + (C1-4 alkyl)4 salts are included. The present disclosure also contemplates the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water- or oil-soluble or dispersible products may be obtained by such quaternization.

[0094] Basic addition salts include pharmaceutically acceptable metal salts and amine salts. Suitable metal salts include sodium, potassium, calcium, barium, zinc, magnesium, and aluminum. Sodium and potassium salts are usually preferred. Further pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed with counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkylsulfonates, and arylsulfonates, where appropriate. Suitable inorganic base addition salts are prepared from metal bases including sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, and the like. Suitable amine base addition salts are prepared from amines that are frequently used in medicinal chemistry due to their low toxicity and acceptability for medical use. Ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, dicyclohexylamine, etc.

[0095] Other acids and bases may be used in the preparation of salts which, while not themselves pharma- ceutically acceptable, are useful as intermediates in obtaining the compounds described herein and their pharma- ceutically acceptable acid or base addition salts.

[0096] The components of the combination may include mixtures / combinations of different pharma- ceutically acceptable salts, as well as mixtures / combinations of the compound in free form and a pharma- ceutically acceptable salt.

[0097] The components of the combination can exist in the form of a solvate. The term "solvate" refers to a molecular complex of a compound (including its salts) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical field that are known to be harmless to the recipient, such as water, ethanol, dimethylsulfoxide, acetone and other common organic solvents. The term "hydrate" refers to a molecular complex that includes a compound and water.

[0098] Pharmaceutical Compositions The compounds described herein can be formulated into pharmaceutical compositions that further comprise a pharma- ceutically acceptable carrier, diluent, adjuvant, or vehicle. In some embodiments, the present disclosure relates to pharmaceutical compositions that comprise the compounds described herein and a pharma- ceutically acceptable carrier, diluent, adjuvant, or vehicle. In some embodiments, the present disclosure includes pharmaceutical compositions that comprise a safe and effective amount of the compounds described herein or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier, diluent, adjuvant, or vehicle. Pharmaceutically acceptable carriers include, for example, pharmaceutical diluents, excipients, or carriers that are suitably selected with respect to the intended administration form and are consistent with conventional pharmaceutical practice.

[0099] "Effective amount" includes "therapeutically effective amount" and "prophylactically effective amount." The term "therapeutically effective amount" refers to an amount effective to treat and / or ameliorate influenza virus infection in a patient. The term "prophylactically effective amount" refers to an amount effective to prevent and / or substantially reduce the chance or size of occurrence of influenza virus infection.

[0100] Pharmaceutically acceptable carrier may contain inactive ingredients that do not excessively inhibit the biological activity of compound.Pharmaceutically acceptable carrier must be biocompatible, for example, non-toxic, non-inflammatory, non-immunogenic, or have no other undesirable reaction or side effect when administered to subject.Standard pharmaceutical formulation techniques can be used.

[0101] Pharmaceutically acceptable carriers, adjuvants, or vehicles as used herein include any solvent, diluent, or other liquid vehicle, dispersion or suspension aid, surfactant, isotonicity agent, thickening or emulsifying agent, preservative, solid binder, lubricant, etc., suitable for the particular dosage form desired. Remington's Pharmaceutical Sciences, 16th ed., EW Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharma-ceutically acceptable compositions and known techniques for their preparation. Except where any conventional carrier medium is incompatible with the compounds described herein, for example, by producing any undesirable biological effects or otherwise interacting in a deleterious manner with any other component(s) of the pharma-ceutically acceptable composition, its use is contemplated within the scope of this disclosure.

[0102] As used herein, the phrase "side effects" encompasses unwanted and adverse effects of a therapy (e.g., a prophylactic or therapeutic agent). Side effects are always unwanted, but unwanted effects are not necessarily harmful. Adverse effects from a therapy (such as a prophylactic or therapeutic agent) can be harmful or uncomfortable, or dangerous. Side effects include, but are not limited to, fever, chills, lethargy, gastrointestinal toxicity (including gastric and intestinal ulcers and erosions), nausea, vomiting, neurotoxicity, nephrotoxicities, renal toxicities (including conditions such as papillary necrosis and chronic interstitial nephritis), hepatotoxicity (including elevated serum liver enzyme levels), bone marrow toxicity (including leukopenia, bone marrow suppression, thrombocytopenia, and anemia), xerostomia, metallic taste, prolonged gestation, weakness, somnolence, pain (including myalgia, bone pain, and headache), alopecia, asthenia, dizziness, extrapyramidal symptoms, akathisia, cardiovascular disorders, and sexual dysfunction.

[0103] Examples of materials which may function as pharma- ceutically acceptable carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as twin80, phosphates, glycine, sorbic acid, or potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, or zinc salts), colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, methylcellulose, hydroxypropylmethylcellulose, wool fat, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives, for example, sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; tragacanth powder; malt; gelatin; talc; cocoa butter and suppository waxes. Excipients such as waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, phosphate buffer solution, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening agents, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition according to the judgment of the formulation manufacturer.

[0104] Formulations for Pulmonary Delivery In some embodiments, the pharmaceutical compositions described herein are adapted to be administered directly to the lower respiratory tract (e.g., lungs) through the respiratory tract by inhalation. Compositions for administration by inhalation may take the form of inhalable powder compositions or liquid or powder sprays and can be administered in standard form using powder inhalers or aerosol dispensing devices. Such devices are well known. For administration by inhalation, powder formulations typically contain the active compound together with an inert solid powder diluent, such as lactose or starch. Inhalable dry powder compositions can be provided in capsules and cartridges of gelatin or similar material, or blisters of laminated aluminum foil for use in an inhaler or insufflator. Each capsule or cartridge can generally contain, for example, about 10 mg to about 100 g of each active compound. Alternatively, the compositions described herein can be provided without excipients.

[0105] Inhalable composition can be packaged for unit dose or multiple dose delivery.For example, composition can be packaged for multiple dose in the same manner as described in GB2242134, U.S. Patent No. 6,632,666, U.S. Patent No. 5,860,419, U.S. Patent No. 5,873,360 and U.S. Patent No. 5,590,645 (all referring to "Diskus" device), or GB2i78965, GB2129691, GB2169265, U.S. Patent No. 4,778,054, U.S. Patent No. 4,811,731 and U.S. Patent No. 5,035,237 (referring to "Diskhaler" device), or EP69715 ("Turbuhaler" device), or GB2064336 and U.S. Patent No. 4,353,656 ("Rotahaler" device).

[0106] Spray compositions for localized delivery to the lungs by inhalation can be formulated as aqueous solutions or suspensions using suitable liquefied propellants, including hydrofluoroalkanes such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, particularly 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane, and mixtures thereof, or as aerosols delivered from pressurized packs such as metered dose inhalers (MDIs). Aerosol compositions suitable for inhalation can be provided as either suspensions or solutions.

[0107] Medicaments for administration by inhalation typically have a controlled particle size. The optimal particle size for inhalation into the bronchial system is usually about 1 to about 10 μm, and in some embodiments, about 2 to about 5 μm. Particles having a size greater than about 20 μm are generally too large to reach the small airways upon inhalation. To achieve these particle sizes, particles of the active ingredient may be subjected to a size reduction process such as micronization. The desired size fraction may be separated by air classification or sieving. Preferably, the particles are crystalline.

[0108] Nasal sprays may be formulated using aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acids or alkalies to adjust the pH, isotonicity adjusting agents or antioxidants.

[0109] Solutions for inhalation by nebulization can be formulated using aqueous vehicles with the addition of agents such as acids or alkalis, buffer salts, isotonicity adjusting agents, or antibacterial agents. They can be sterilized by filtration or heating in an autoclave, or provided as non-sterile products. Nebulizers deliver aerosols as a mist generated from the aqueous formulation.

[0110] In some embodiments, the pharmaceutical compositions described herein can be formulated with supplementary active ingredients.

[0111] In some embodiments, the pharmaceutical compositions described herein are administered from a dry powder inhaler.

[0112] In other embodiments, the pharmaceutical compositions described herein are administered by an aerosol dispensing device, optionally in combination with an inhalation chamber, such as a "Volumatic"® inhalation chamber.

[0113] The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and / or vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating agent such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms in the compositions described herein is achieved by adding antibacterial and / or antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it is desirable to include an isotonic agent, for example, sugar or sodium chloride. Prolonged absorption of the injectable composition can be brought about by the use of agents that delay absorption, for example, aluminum monostearate and gelatin, in the composition.

[0114] In some embodiments, the pharmaceutical compositions described herein can be in a matrix that controls the release of the composition. In some embodiments, the matrix can be a lipid, polyvinyl alcohol, polyvinyl acetate, polycaprolactone, poly(glycolic) acid, poly(lactic) acid, polycaprolactone, polylactic acid, polyanhydrides, polylactide-co-glycolide, polyamino acids, polyethylene oxide, acrylic-terminated The matrix may include poly(tertiary olefins), ...

[0115] Pharmaceutically acceptable carriers and / or diluents may include any solvent, dispersion medium, coating agent, antibacterial and / or antifungal agent, isotonic agent and absorption delaying agent, etc. The use of such media and agents for pharma-ceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the pharmaceutical composition is contemplated.

[0116] The pharmaceutical compositions of the present disclosure can be formulated for administration according to conventional techniques. See, e.g., Remington, The Science and Practice of Pharmacy (20th Ed. 2000). For example, the intranasal pharmaceutical compositions of the present disclosure can be formulated as aerosols (which term includes both liquid and dry powder aerosols). Aerosols of liquid particles can be generated by any suitable means, such as pressure-driven aerosol nebulizers or ultrasonic nebulizers, as known to those skilled in the art. See, e.g., U.S. Pat. No. 4,501,729. Similarly, aerosols of solid particles (e.g., lyophilized, freeze dried, etc.) can be generated in any solid particle pharmaceutical aerosol generating device by techniques known in the pharmaceutical industry. As another example, the pharmaceutical compositions of the present disclosure can be formulated as on-demand dissolvable forms that provide a lyophilized portion of the pharmaceutical composition and a dissolved solution portion of the pharmaceutical composition.

[0117] In some embodiments of the present disclosure, the pharmaceutical composition is in the form of an aqueous suspension, which can be prepared from a solution or suspension.With respect to a solution or suspension, the dosage form can be composed of lipophilic substances, liposomes (phospholipid vesicles / membranes), and / or micelles of fatty acids (e.g. palmitic acid).In certain embodiments, the pharmaceutical composition is a solution or suspension that can dissolve in the liquid secreted by the epithelial mucosa of the tissue to which the pharmaceutical composition is administered, applied, and / or delivered, which can advantageously enhance absorption.

[0118] The pharmaceutical composition can be an aqueous solution, a non-aqueous solution, or a combination of aqueous and non-aqueous solutions.

[0119] Suitable aqueous solutions may include, but are not limited to, aqueous gels, aqueous suspensions, aqueous microsphere suspensions, aqueous microsphere dispersions, aqueous liposomal dispersions, aqueous micelles of liposomes, aqueous microemulsions, and any combination of the above, or any other aqueous solution that can be dissolved in the fluid secreted by the mucous membrane of the nasal cavity. Exemplary non-aqueous solutions may include, but are not limited to, non-aqueous gels, non-aqueous suspensions, non-aqueous microsphere suspensions, non-aqueous microsphere dispersions, non-aqueous liposomal dispersions, non-aqueous emulsions, non-aqueous microemulsions, and any combination of the above, or any other non-aqueous solution that can be mixed or dissolved in the fluid secreted by the mucous membrane.

[0120] Examples of powder formulations include, but are not limited to, simple powder mixtures, micronized powders, freeze-dried powders, lyophilized powders, powder microspheres, coated powder microspheres, liposomal dispersions, and any combination of the above. Powder microspheres can be formed from a variety of polysaccharides and celluloses, including, but not limited to, starch, methylcellulose, xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, carbomer, polyvinyl alcohol alginate, acacia, chitosan, and any combination thereof.

[0121] In certain embodiments, the inhalable compositions are those that are at least partially, or even substantially (e.g., at least 80%, 90%, 95% or more) soluble in fluids secreted by mucous membranes to facilitate absorption. The compositions can be formulated with carriers and / or other substances that facilitate dissolution of the agent in the secretions, including, but not limited to, fatty acids (e.g., palmitic acid), gangliosides (e.g., GM-1), phospholipids (e.g., phosphatidylserine), and emulsifiers (e.g., polysorbate 80).

[0122] Those skilled in the art will appreciate that in intranasal administration or delivery, the volume of pharmaceutical composition administered is generally small, and nasal secretions may alter the pH of the administered dose, since the pH range in the nasal cavity can be as broad as 5-8. Such alterations can affect the concentration of non-ionized drug available for absorption. Thus, in representative embodiments, the pharmaceutical composition further comprises a buffer to maintain or adjust the pH in situ. Exemplary buffers include, but are not limited to, ascorbate, acetate, citrate, prolamin, carbonate, and phosphate buffers.

[0123] In some embodiments, the pH of the pharmaceutical composition is selected so that the internal environment of the mucosal tissue after administration is neutral or acidic, which (1) can provide the active compound in a non-ionized form for absorption, (2) inhibit the growth of pathogenic bacteria that are more likely to occur in an alkaline environment, and (3) reduce the potential for irritation of the mucosa.

[0124] For liquid and powder spray or aerosol, pharmaceutical compositions can be formulated to have any suitable and desired particle or droplet size.In exemplary embodiments, the majority and / or average size of particles or droplets is in the range of about 1, 2.5, 5, 10, 15, or 20 microns or more, and / or about 25, 30, 40, 45, 50, 60, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, or 425 microns or less (including all combinations of the above). Representative examples of suitable ranges of bulk and / or average particle or droplet size include, but are not limited to, about 5-100 microns, about 10-60 microns, about 175-325 microns, and about 220-300 microns, which promote deposition of a safe and effective amount of active compound, for example, in the nasal cavity (e.g., the upper third of the nasal cavity, superior nasal meatus, olfactory region, and / or paranasal sinus region to target the olfactory nerve pathway). Generally, particles or droplets smaller than about 5 microns will deposit in the trachea or even the lungs, while particles or droplets of about 50 microns or larger will generally not reach the nasal cavity and will deposit in the anterior nose.

[0125] International Patent Publication No. WO2005 / 023335 describes particles and droplets having diameter sizes suitable for the practice of exemplary embodiments of the present disclosure. In certain embodiments, the particles or droplets have an average diameter of about 5-30 microns, about 10-20 microns, about 10-17 microns, about 10-15 microns, about 12-17 microns, about 10-15 microns, or about 10-12 microns. The particles can have "substantially" the average diameters or sizes described herein, i.e., at least about 50%, 60%, 70%, 80%, 90%, or 95% or more of the particles are of the indicated diameter or size range.

[0126] The pharmaceutical compositions described herein can be delivered as an atomized or misted liquid having droplet sizes as described above.

[0127] According to certain embodiments involving intranasal delivery methods, it may be desirable to extend the residence time of the pharmaceutical composition in the nasal cavity (e.g., in the upper third of the nasal cavity, the superior meatus, the olfactory region, and / or in the paranasal sinus region), for example, to enhance absorption. Thus, the pharmaceutical composition may be optionally formulated with agents that extend residence time in the nasal cavity, such as bioadhesive polymers, gums (e.g., xanthan gum), chitosan (e.g., highly purified cationic polysaccharides), pectin (or any carbohydrate that thickens like a gel or emulsion when applied to the nasal mucosa), microspheres (e.g., starch, albumin, dextran, cyclodextrin), gelatin, liposomes, carbamers, polyvinyl alcohol, alginates, acacia, chitosan, and / or cellulose (e.g., methyl or propyl, hydroxyl or carboxy, carboxymethyl or hydroxylpropyl). As an additional approach, increasing the viscosity of the formulation may also provide a means of extending the contact of the agent with the nasal epithelium. Pharmaceutical compositions can be formulated as nasal emulsions, ointments, or gels, which offer advantages for topical application due to their viscosity.

[0128] A moist and highly vascularized membrane can promote rapid absorption. As a result, the pharmaceutical composition can optionally contain a moisturizer, especially in the case of a gel-based composition, to ensure sufficient intranasal water content. Examples of suitable moisturizers include, but are not limited to, glycerin or glycerol, mineral oil, vegetable oil, membrane conditioners, soothing agents, and / or sugar alcohols (e.g., xylitol, sorbitol, and / or mannitol). The concentration of moisturizer in the pharmaceutical composition varies depending on the selected drug and formulation.

[0129] The pharmaceutical composition may also optionally include an absorption enhancer, such as an agent that inhibits enzyme activity, reduces mucus viscosity or elasticity, reduces mucociliary clearance effect, opens tight junctions, and / or solubilizes the active compound. Chemical enhancers are known in the art and include chelating agents (e.g., EDTA), fatty acids, bile salts, surfactants, and / or preservatives. Penetration enhancers may be particularly useful when formulating compounds that exhibit low membrane permeability, lack of lipophilicity, and / or are degraded by aminopeptidases. The concentration of absorption enhancer in the pharmaceutical composition varies depending on the agent and formulation selected.

[0130] Preservatives can be optionally added to pharmaceutical compositions to extend shelf life.Suitable preservatives include, but are not limited to, benzyl alcohol, parabens, thimerosal, chlorobutanol, and benzalkonium chloride, and combinations of the above.The concentration of preservatives varies depending on the preservative used, the compound to be formulated, the formulation, etc.In a representative embodiment, the preservative is present in an amount of about 2% by weight or less.

[0131] The pharmaceutical compositions described herein can optionally include an odorant, e.g., as described in European Patent No. EP0504263B1, to provide an odor to aid in inhalation of the composition to facilitate delivery to the olfactory region and / or to induce transport by olfactory neurons.

[0132] Alternatively, the composition may include flavoring agents, for example to enhance the taste and / or acceptability of the composition to a subject.

[0133] Porous particles for pulmonary administration In some embodiments, the particles are porous such that they have an appropriate density to avoid deposition in the back of the throat when administered via an inhaler. The combination of a relatively large particle size and a relatively low density avoids phagocytosis in the lungs and provides a well targeted delivery, avoids systemic delivery of the component, and provides a high concentration of the component in the lungs.

[0134] Representative methods for preparing such particles and delivering such particles are described, for example, in U.S. Pat. No. 7,384,649, U.S. Pat. No. 7,182,961, U.S. Pat. No. 7,146,978, U.S. Pat. No. 7,048,908, U.S. Pat. No. 6,956,021, U.S. Pat. No. 6,766,799, and U.S. Pat. No. 6,732,732.

[0135] Additional patents disclosing such particles include U.S. Patent No. 7,279,182, U.S. Patent No. 7,252,840, U.S. Patent No. 7,032,593, U.S. Patent No. 7,008,644, U.S. Patent No. 6,848,197, and U.S. Patent No. 6,749,835.

[0136] No. 7,678,364 describes a method for administering to the airways of a patient in need of treatment, prevention, or diagnosis a) a polyvalent metal cation complexed with a therapeutic, prophylactic, or diagnostic agent, b) a pharma- ceutically acceptable carrier, and c) a dry powder comprising a total amount of polyvalent metal cation that is about 10% w / w or more of the total weight of the agent, about 0.4 g / cm, which is spray dried. 3 Disclosed is a method for delivering particles to the pulmonary system comprising administering a safe and effective amount of a dry powder comprising a polyvalent metal cation-containing component having the following tap density: a median geometric diameter of about 5 micrometers to about 30 micrometers, and an aerodynamic diameter of about 1 to about 5 microns.

[0137] The amount of a compound described herein or a salt thereof present in the particles can range from about 0.1% to about 95% by weight, but in some cases can be as high as 100%, for example, from about 1 to about 50% by weight, such as from about 5 to about 30% by weight. Particles in which the drug is distributed throughout the particle can be preferred.

[0138] In some embodiments, the particles contain surfactants other than the above-mentioned phospholipids. As used herein, the term "surfactant" refers to any agent that preferentially absorbs into the interface between two immiscible phases, such as the interface between water and an organic polymer solution, the water / air interface, or the organic solvent / air interface. Surfactants generally have hydrophilic and lipophilic portions, so that when absorbed into particles, they tend to present portions to the external environment that do not attract similarly coated particles, thus reducing particle aggregation. Surfactants can also facilitate the absorption of therapeutic or diagnostic agents and increase the bioavailability of the agents.

[0139] Suitable surfactants that can be used in the manufacture of the particles described herein include, but are not limited to, hexadecanol; fatty alcohols such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; surface active fatty acids such as palmitic acid or oleic acid; glycocholate; surfactin; poloxamer; sorbitan fatty acid esters such as sorbitan trioleate (Span 85); Tween® 80 and tyloxapol.

[0140] The surfactant may be present in the particles in an amount ranging from about 0 to about 5% by weight. Preferably, the surfactant may be present in the particles in an amount ranging from about 0.1 to about 1% by weight, for example, 1.0% by weight.

[0141] Approximately 0.4g / cm 3Particles having a tap density of less than about 1 μm, a median diameter of at least about 5 μm, and an aerodynamic diameter of about 1 μm to about 5 μm or about 1 μm to about 3 μm are better able to avoid inertial and gravitational deposition in the oropharyngeal region and are targeted to the airways or deep lung. The use of larger, more porous particles is advantageous because they can be aerosolized more efficiently than smaller, denser particles such as those currently used for inhalation therapy.

[0142] Liposome Delivery The compositions described herein are advantageously delivered to the lungs to provide the compounds at the site of actual or potential influenza infection. This can be accomplished by pulmonary delivery via a metered dose inhaler or other pulmonary delivery device, or by accommodation of the particles in the capillary bed surrounding the alveoli of the lungs.

[0143] Nanocarriers, such as liposomes, which contain small unilamellar vesicles, show several advantages over other conventional approaches to deliver drugs to the lung, such as long-term drug release and cell-specific targeted drug delivery. Nano-sized drug carriers can also be advantageous for the delivery of poorly water-soluble drugs, and certain compounds described herein are poorly water-soluble. Additional advantages include the ability to provide controlled release, protection from metabolism and degradation, reduced drug toxicity, and targeting capabilities.

[0144] Liposomes (preferably unilamellar vesicles) are characterized by having a size of less than 200 nm as measured by dynamic light scattering, being composed of chemically pure synthetic phospholipids, most preferably containing a side chain of at least 16 carbons in length, containing one or more compounds as described herein or their pharma- ceutically acceptable salts, sufficient to preferentially deliver (i.e., target) a certain amount of said compounds to the capillary bed surrounding the alveoli.The diameter of vesicles can be measured by dynamic light scattering, for example, using a helium-neon 100mW NEC gas laser and a Malvern K7027 correlator, and ideally, at least two or three measurements are taken for each size determination.

[0145] The expression "chemically pure phospholipids" is meant to define phospholipids that are essentially free of deleterious surfactant moieties and impurities (which cause aggregation of small unilamellar vesicles (SUVs) formed from them) and are greater than 97% pure. Preferably, the liposomes incorporate phospholipids that have a diameter of about 50 to about 160 nm, are essentially neutral in charge, and have a side chain length of 16 to 18 carbon atoms. More preferably, the liposomes are prepared from distearoylphosphatidylcholine (DSPC) and contain cholesterol (most preferably in an amount of 10 to 50% of the total lipid) as a vesicle stabilizer.

[0146] It can also be advantageous for the liposomes to have a melting point above body temperature (i.e., above 37°C). For this reason, it can be advantageous to use pure phospholipids, preferably saturated and with a carbon chain length of at least 16 carbons, preferably 16-18 carbons. Distearoylphosphatidylcholine (DSPC) is the preferred phospholipid. Cholesterol helps stabilize the liposomes and is preferably added in an amount sufficient to provide liposomal stability. Most preferably, the liposomes further comprise a PEGylated phospholipid, such as DSPEPEG. The method includes introducing into the patient's bloodstream a quantity of liposomes (preferably unilamellar vesicles) that are less than 200 nm in size, preferably comprised of chemically pure synthetic phospholipids, most preferably comprising a side chain at least 16 carbons in length, and containing a compound as described herein or a pharma- ceutically acceptable salt or prodrug thereof, sufficient to preferentially deliver (i.e., target) a quantity of the compound to the pulmonary capillary bed surrounding the alveoli.

[0147] The compounds described herein can be combined with other anti-influenza agents as described herein. Such additional agents can be present in the liposome, can be present in different liposomes, or can be co-administered via different routes.

[0148] The liposomes contain one or more of the compounds described herein or pharma- ceutically acceptable salts thereof, and can optionally contain other anti-influenza agents. The liposomes can be prepared by dissolving phospholipids and cholesterol in a suitable organic solvent, such as chloroform, and evaporating the solvent to form a lipid film. If an ionophore is used to load the compounds described herein into the liposomes, the ionophore can be added to the lipid solution before evaporation. The dried lipid film is then rehydrated with a suitable aqueous phase, such as phosphate buffered saline or other physiologically suitable solution. Water-soluble drugs or therapeutic agents can be included in the hydration solution, but if remote loading is desired, loading agents, such as the chelating agents described above, can be added to the hydration solution to encapsulate within the internal aqueous space of the liposome.

[0149] Upon addition of the hydration solution, liposomes of various sizes spontaneously form and encapsulate a portion of the aqueous phase. The liposomes and aqueous suspension are then subjected to shear forces, such as extrusion, sonication, or treatment with a homogenizer, according to the methods described in U.S. Patent No. 4,753,788, to generate vesicles of specific sizes.

[0150] The liposomes can then be treated to remove undesirable compounds, such as unencapsulated drug, from the suspension solution, which can be accomplished by processes such as gel chromatography or ultrafiltration.

[0151] The use of liposomes in dry powder aerosols for targeted pulmonary delivery is described, for example, in Willis et al., Lung, June 2012, 190(3):251-262.

[0152] Method of administration The compounds and pharma- ceutically acceptable compositions described above can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (such as by powder, ointment, or drops), buccally, orally or as a nasal spray to the pulmonary system, such as by use of an inhaler, such as a metered dose inhaler (MDI), depending on the severity of the infection to be treated.

[0153] Liquid dosage forms for oral administration include, but are not limited to, pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.In addition to active compounds, liquid dosage forms can contain inert diluents commonly used in the art, such as water or other solvents, solubilizers, and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, EtOAc, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, and mixtures thereof.In addition to inert diluents, oral compositions can also contain auxiliary agents, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and aromatic agents.

[0154] Injectable preparations, for example, injectable sterile aqueous or oleaginous suspensions, can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations can also be injectable sterile solutions, suspensions or emulsions in non-toxic parenterally acceptable diluents or solvents, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution, USP, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as solvents or suspending media. For this purpose, any bland fixed oil can be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[0155] The injectable preparations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other injectable sterile medium prior to use.

[0156] In order to prolong the effect of the compounds described herein, it is often desirable to delay the absorption of the compounds from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends on its dissolution rate, which in turn may depend on the crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer and the nature of the particular polymer used, the drug release rate can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Injectable depot formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[0157] Compositions for rectal or vaginal administration are specifically suppositories, which can be prepared by mixing the compounds described herein with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol or a suppository wax, which is solid at ambient temperature but liquid at body temperature and thus melts in the rectum or vaginal cavity to release the active compound.

[0158] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharma- ceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants, such as glycerol; d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents, such as paraffin; f) absorption accelerators, such as quaternary ammonium compounds; g) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; h) absorbents, such as kaolin and bentonite clay; and i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may comprise buffering agents.

[0159] Similar types of solid compositions may be used as fillers for soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols. The solid dosage forms of tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells such as enteric coatings and other coatings well known in the art of pharmaceutical formulation. They may optionally contain opacifying agents, and may also be of a composition that releases the active ingredient only or preferentially in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that may be used include polymeric substances and waxes. Similar types of solid compositions may be used as fillers for soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols.

[0160] The active compound can also be in microencapsulated form with one or more excipients as described above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings, release-controlling coatings, and other coatings well known in the art of pharmaceutical formulation. In such solid dosage forms, the active compound can be mixed with at least one inert diluent, such as sucrose, lactose, or starch. Such dosage forms can also contain, as is common practice, additional substances other than inert diluents, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage forms can also contain buffering agents. They can optionally contain opacifying agents, and can also be of a composition that releases the active ingredient only or preferentially in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0161] Dosage forms for topical or transdermal administration of the compounds described herein include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active ingredient is mixed under sterile conditions with a pharma- ceutically acceptable carrier and any necessary preservatives or buffers as required. Ophthalmic formulations, ear drops, and eye drops are also contemplated to be within the scope of the present disclosure. In addition, the present disclosure contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in a suitable medium. Absorption enhancers can be used to increase the flux of the compound across the skin. The rate can be controlled by providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.

[0162] The compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, vaginally, or via an implanted reservoir. The term "parenteral" as used herein includes, but is not limited to, subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Specifically, the compositions are administered orally, intraperitoneally, or intravenously.

[0163] The injectable sterile forms of the compositions described herein may be aqueous or oleaginous suspensions. These suspensions can be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The injectable sterile preparations can also be injectable sterile solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as a solvent or suspending medium. For this purpose, any bland fixed oil can be used, including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharma-ceutically acceptable oils such as olive oil or castor oil, especially in their polyoxyethylated form. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose, or similar dispersants commonly used in the formulation of pharma- ceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tween, Span, and other emulsifiers or bioavailability enhancers, commonly used in the manufacture of pharma- ceutically acceptable solid, liquid, or other dosage forms, may also be used for formulation purposes.

[0164] The pharmaceutical compositions described herein can be orally administered in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions or solutions.For tablets for oral use, commonly used carriers include but are not limited to lactose and corn starch.Lubricants such as magnesium stearate are also typically added.For oral administration in capsule form, useful diluents include lactose and dried corn starch.When aqueous suspensions are required for oral use, active ingredient is combined with emulsifying and suspending agents.If desired, certain sweeteners, flavors or colorants can also be added.

[0165] Alternatively, the pharmaceutical compositions described herein can be administered in the form of suppositories for rectal administration.These can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature, and therefore melts in the rectum to release the drug.Such materials include, but are not limited to, cocoa butter, beeswax, and polyethylene glycol.

[0166] The pharmaceutical compositions described herein may also be administered topically, particularly when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0167] Topical application for the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topical-transdermal patches may also be used.

[0168] For topical application, the pharmaceutical composition can be formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers.Carriers for topical administration of the compounds described herein include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water.Alternatively, the pharmaceutical composition can be formulated into a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharma- ceutically acceptable carriers.Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[0169] For ophthalmic use, the pharmaceutical composition may be formulated as a micronized suspension in isotonic pH-adjusted sterile saline or, specifically, as a solution in isotonic pH-adjusted sterile saline with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic use, the pharmaceutical composition may be formulated in an ointment such as petrolatum.

[0170] The compounds for use in the methods described herein can be formulated in unit dosage form. The term "unit dosage form" refers to a physically separate unit suitable as a unit and dose for the subject to be treated, each unit containing a predetermined amount of active material calculated to produce a desired therapeutic effect, optionally with a suitable pharmaceutical carrier. The unit dosage form can be for a single daily dose or multiple daily doses (e.g., about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form can be the same or different for each dose.

[0171] The present disclosure will be more fully understood by reference to the following examples which detail exemplary embodiments. They should not, however, be construed as limiting the scope of the disclosure. All citations throughout this disclosure are expressly incorporated herein by reference. EXAMPLES

[0172] Example 1 - Cytopathic Effect Assay A study was conducted to evaluate the in vitro combination effects of the test compound 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid with other influenza antiviral drugs in an influenza virus cell-based assay for cytopathic effect (CPE).

[0173] Influenza virus A / PR / 8 / 34(H1N1) (ATCC VR-1469) was obtained from ATCC. MDCK cells (ATCC CCL-34) were obtained from ATCC and maintained in Minimal Essential Medium Eagle (Sigma M2279) supplemented with 10% fetal bovine serum (Corning R35-076-CV), 1% L-glutamine (Gibco 25030081), 1% non-essential amino acids (NEAA, Gibco 11140050), and 1% penicillin-streptomycin (PS, Hyclone SV30010).

[0174] The test medium for MDCK cells was OptiPRO SFM medium (Gibco 12309019) supplemented with 1% L-glutamine, 1% NEAA, 1% PS, and 2.5 μg / mL trypsin was used as the test medium for MDCK cells.

[0175] MDCK cells were seeded at 2,000 cells per well in 384-well plates and incubated overnight at 37°C, 5% CO2. The following day, each of the two drug combination pairs was tested in triplicate plates using a checkerboard cross pattern of seven drug concentrations of each compound, including each compound alone. Pimodivir (VX-787) was evaluated in parallel as a control compound. Compounds (in DMSO) were plated with a Tecan HP D300 digital dispenser. Virus (2 TCID 90Compounds were tested at concentrations of 0.125, 0.25, 0.5, 1, 2, 4, and 8×EC 50 The values ​​were 0.5%. The compound combinations are shown in Table 4. The final concentration of DMSO (Sigma 34869) in the cell culture medium was 0.5%. The resulting cultures were incubated at 37°C and 5% CO2 for an additional 5 days until the virus infection in the virus control displayed significant CPE (as assessed by a reduction in the number of viable cells). Then, to assess cell viability, CCK-8 kit solution (1-bottle colorimetric system, Biolite 35004) was added to each well and the cells were incubated at 37°C for 3 hours. The absorbance (460 nm) was measured using a SpectraMax 340PC384 plate reader (Molecular Devices). The antiviral activity and cytotoxicity of the compound combinations were expressed as % inhibition and % viability, respectively, and calculated by the following formulas: Inhibition (%) = (raw data cpd- average VC ) / (average CC- average VC ) * 100 Survival rate (%) = (raw data cpd- average MC ) / (average CC- average MC ) * 100 Raw Data cpd represents the absorbance value of compound-treated wells. Mean VC ,average CC , and the average MC are the average absorbance values ​​of the virus control (VC; cells infected with virus, no compound), cell control (CC; cells without virus or compound), and medium control (MC, medium only), respectively. Combination indexes were calculated using MacSynergy™ II software (Prichard and Shipman, 1990). Synergy amount plots (95%) were then calculated. Positive combination index values ​​indicate synergy, and negative combination index values ​​indicate antagonism.

[0176] As shown in the table below, 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid exhibited strong synergy with influenza antivirals including baloxavir (free hydroxyl form of baloxavir marboxyl prodrug), oseltamivir acid, and favipiravir in influenza antiviral CPE assay against IFV A / PR / 8 / 34(H1N1). [Table 1]

[0177] An absolute combination index value of less than 25 (i.e., 95% synergy) indicates an additive effect. An absolute combination index value of 25-50 indicates slight synergy or antagonism. An absolute combination index value of 50-100 indicates moderate synergy or antagonism. An absolute combination index value of greater than 100 indicates strong synergy or antagonism.

[0178] Figures 1-3 provide visual representations of the plots calculated for each of the three test combinations.

[0179] These same three combinations of Compound 1 with baloxavir (the free hydroxyl form of the baloxavir marboxyl prodrug), oseltamivir acid, and favipiravir also exhibit antiviral activity against influenza B.

Claims

1. 1. A pharmaceutical combination for use in the treatment or prevention of influenza virus infection or replication, comprising 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharmaceutically acceptable salt or solvate thereof, and a second antiviral agent selected from the group consisting of baloxavir, baloxavir marboxil, oseltamivir, oseltamivir acid and favipiravir, and pharmaceutically acceptable salts or solvates thereof.

2. The pharmaceutical combination of claim 1 , wherein the second antiviral agent is a neuraminidase inhibitor, a polymerase inhibitor or an endonuclease inhibitor.

3. 2. The pharmaceutical combination of claim 1, wherein the second antiviral agent is a neuraminidase inhibitor selected from oseltamivir and oseltamivir acid, and pharma- ceutically acceptable salts or solvates thereof.

4. 2. The pharmaceutical combination of claim 1, wherein the second antiviral agent is an endonuclease inhibitor selected from baloxavir marboxil and baloxavir, and pharma- ceutically acceptable salts or solvates thereof.

5. 2. The pharmaceutical combination of claim 1, wherein the second antiviral agent is a polymerase inhibitor selected from favipiravir and its pharmaceutical acceptable salts or solvates.

6. The pharmaceutical combination of claim 1 , wherein the second antiviral agent further comprises an influenza vaccine.

7. 2. The pharmaceutical combination of claim 1, wherein the 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid or a pharma- ceutically acceptable salt or solvate thereof and the second antiviral agent are co-formulated.

8. The combination pharmaceutical of claim 1, wherein the 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid or a pharma- ceutically acceptable salt or solvate thereof and the second antiviral agent are contained in separate formulations.

9. The pharmaceutical combination according to any one of claims 1 to 8, wherein the influenza virus is a pandemic influenza virus or a drug-resistant pandemic / seasonal influenza virus.

10. The pharmaceutical combination according to any one of claims 1 to 6 for use in the treatment or prevention of influenza A or influenza B infection in a host.

11. The pharmaceutical combination of claim 10, wherein the treatment further comprises a therapeutically effective amount of a third antiviral agent.

12. 1. A pharmaceutical combination for use in the treatment or prevention of influenza virus infection or replication, comprising: a) 3-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid, or a pharma- ceutically acceptable salt or solvate thereof, b) baloxavir, baloxavir marboxil, or a pharma- ceutically acceptable salt or solvate thereof, and c) a neuraminidase inhibitor.

13. The pharmaceutical combination according to claim 12, wherein the neuraminidase inhibitor is oseltamivir, oseltamivir acid, zanamivir, laninamivir, peramivir, or a pharma- ceutically acceptable salt or solvate thereof.

14. 14. The pharmaceutical combination according to claim 12 or 13 for use in the treatment or prevention of influenza A or influenza B infection in a host.

Citation Information

Patent Citations

  • Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with Anti-influenza drug

    WO2017104691A1

  • Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

    WO2018200425A1